European Commission Approves Pfizer's LITFULO™ for Adolescents and Adults With Severe Alopecia Areata | Region
NEW YORK--(BUSINESS WIRE)--Sep 19, 2023--
Source: eagletribune.com
Page 3 - Retrospective Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Retrospective Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Retrospective Study Today - Breaking & Trending Today
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
CORAL GABLES, Fla., Aug. 14, 2023 -- Catalyst Pharmaceuticals, Inc. , a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel... -Today at 08:06 am- MarketScreener
Source: marketscreener.com
Backyard farming top ASF risk factor – study
THE Philippine Council for Agriculture and Fisheries (PCAF) reported that backyard farming is the number one risk factor associated with the spread of the African swine fever (ASF) in the Philippines.
Source: manilatimes.net
FDA Approves Pfizer's LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata | Region
NEW YORK--(BUSINESS WIRE)--Jun 23, 2023--
Source: eagletribune.com
FDA Approves Pfizer's LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata - Pfizer (NYSE:PFE)
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12 Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved
Source: benzinga.com